Catalog # 10-3231
Cabozantinib

CAS# 849217-68-1

N-(4-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

XL-184; BMS-907351; Carbozantinib

Lot # X107856



Novel inhibitor of c-met and VEGFR2 kinase activity, IC_{50}=3.5 nm and 35 pM respectively.[1] Inhibits MET-activating kinase domain mutations Y1248H, D1246N or K1262R, IC_{50}=3.8, 11.8 and 14.6 nM respectively. In cellular assays it inhibits the following kinases: MET, VEGF2, KIT, FLT3 and AXL, IC_{50}=7.8, 1.9, 5.0, 7.5 and 42 μM respectively.[1] Eliminated approximately 80% of vasculature in spontaneous pancreatic islet tumors over 7 days in a mouse model.[2] Clinically useful anticancer agent.[3]

1) Yakes et al. (2011), *Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth*; Mol. Cancer Ther., **10** 2298
2) You *et al*. (2011), *VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer*; Cancer Res., **71** 4758
3) Kurzrock *et al*. (2011), *Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor in patients with medullary thyroid cancer*; J. Clin. Oncol., **29** 2660

PHYSICAL DATA

Molecular Weight:	501.51
Molecular Formula:	$C_{28}H_{24}FN_3O_5$
Purity:	98% by HPLC NMR: (Conforms)
Solubility:	Soluble in DMSO
Physical Description:	White solid
Storage and Stability:	Store as supplied desiccated at -20°C for up to 1 year from the date of purchase. Solutions in DMSO may be stored at -20°C for up to 3 months.

Focus Biomolecules LLC 400 Davis Drive, Suite 600 Plymouth Meeting PA 19462

www.focusbiomolecules.com